Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics

Global Anti-Pollution Skincare Products Market to Reach US$18.1 Billion by 2030

The global market for Anti-Pollution Skincare Products estimated at US$12.4 Billion in the year 2024, is expected to reach US$18.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Anti-Pollution Creams, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$8.3 Billion by the end of the analysis period. Growth in the Anti-Pollution Moisturizers segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 10.4% CAGR

The Anti-Pollution Skincare Products market in the U.S. is estimated at US$3.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Anti-Pollution Skincare Products Market – Key Trends & Drivers Summarized

Why Are Anti-Pollution Skincare Products Becoming a Vital Part of Daily Beauty Regimens?

The demand for anti-pollution skincare products has seen explosive growth in recent years as consumers become increasingly aware of the detrimental effects of urban pollution on skin health. In cities across the globe, rising levels of particulate matter (PM2.5 and PM10), toxic gases, heavy metals, and free radicals pose a constant threat to the skin`s integrity. Prolonged exposure to these pollutants has been linked to premature aging, dullness, pigmentation, inflammation, and the weakening of the skin`s natural barrier. As a result, skincare consumers are now prioritizing products that not only cleanse and hydrate but also offer a protective shield against environmental aggressors. Anti-pollution formulations are being adopted as essential components of morning skincare routines, functioning as invisible armor against smog, UV radiation, and oxidative stress. This shift is particularly pronounced among urban dwellers, commuters, and individuals with sensitive or reactive skin types who notice daily irritation or uneven tone linked to air quality. The rise in dermatological consultations reporting pollution-induced skin conditions has further fueled this trend. Consumers are increasingly researching ingredients and choosing products with claims such as “pollution defense,” “anti-smog,” or “environmental shield.” Additionally, the integration of anti-pollution care into sunscreens, moisturizers, serums, and primers reflects how these concerns have become embedded in broader beauty routines. The growing cultural focus on wellness, self-care, and preventive skincare has solidified the place of anti-pollution products as a standard—not a luxury—in modern skincare.

What Scientific Innovations Are Powering the Effectiveness of Anti-Pollution Skincare Formulations?

The evolution of anti-pollution skincare products has been driven by cutting-edge research in dermatology, biochemistry, and environmental science, resulting in highly effective formulations that go far beyond basic hydration and cleansing. These innovations often center around ingredients that either neutralize environmental toxins, strengthen the skin barrier, or prevent pollutant adhesion to the skin surface. Key bioactive compounds such as antioxidants—especially vitamins C and E, niacinamide, and polyphenols—help combat oxidative stress caused by free radicals. Other ingredients like activated charcoal, bentonite clay, and moringa extract are used for their detoxifying properties, effectively removing impurities from clogged pores. Advanced peptides and ceramides are added to support the skin’s natural lipid barrier, improving its resilience against irritants. Novel encapsulation technologies have also enhanced delivery mechanisms, allowing antioxidants and hydrating agents to penetrate deeper and remain active longer. Some formulations now include biomimetic shields that form breathable films over the skin, physically preventing pollutant particles from adhering to the epidermis. In addition, microbiome-friendly components are being used to protect and balance skin flora, which can be disrupted by environmental aggressors. Research has also led to the use of marine extracts and plant stem cells that have shown promising anti-inflammatory and anti-aging effects under pollution stress. The combination of real-time clinical testing and wearable skin health monitoring tools is helping brands refine formulations to address specific urban pollution profiles. As consumer sophistication grows, products that offer not just marketing claims but scientifically validated results are increasingly preferred, setting a new standard for product efficacy in the skincare industry.

How Are Consumer Behaviors and Lifestyle Shifts Driving Demand for Anti-Pollution Skincare Solutions?

Modern lifestyles—marked by urbanization, increased mobility, and digital engagement—are playing a significant role in accelerating the demand for anti-pollution skincare products. A growing segment of the global population now lives in metropolitan areas where daily exposure to airborne toxins, UV radiation, and even indoor pollutants is unavoidable. The desire to maintain a healthy, youthful complexion in such environments is prompting consumers to invest in targeted skincare that addresses these specific challenges. Work-from-home trends have not reduced the demand for skincare; on the contrary, people are spending more time scrutinizing their appearance on video calls and social media, thereby increasing their focus on skin quality and tone. Rising awareness through health blogs, dermatologists’ advice, beauty influencers, and clean beauty advocates has also educated consumers about the impact of pollution on skin aging, making anti-pollution care a conscious part of their beauty spend. Moreover, the increased popularity of wellness-driven lifestyles is encouraging users to treat skincare as part of a broader ritual of environmental detoxification and self-care. Consumers now prefer multi-functional products that combine pollution defense with hydration, SPF protection, and anti-aging properties. The demand for minimalist, yet high-performance routines is fueling growth in hybrid products like anti-pollution moisturizers with broad-spectrum UV filters or primers that also defend against blue light and particulate matter. Across all age groups, there’s a growing preference for products backed by transparent ingredient lists, ethical sourcing, and sustainability certifications, reflecting a broader shift in lifestyle and consumption values. These behavioral shifts are fundamentally changing how skincare is perceived—not as vanity, but as a necessity for modern living.

What Are the Core Drivers Fueling the Global Market Growth of Anti-Pollution Skincare Products?

The growth in the anti-pollution skincare products market is driven by a powerful convergence of environmental, technological, social, and economic forces. One of the leading drivers is the increase in global pollution levels, particularly in densely populated urban centers across Asia, Latin America, and parts of Europe, where worsening air quality is a persistent public health issue. This environmental crisis is prompting both regulatory scrutiny and personal concern, leading to increased demand for protective skincare solutions. Concurrently, technological advances in ingredient development, product formulation, and dermatological testing have improved product efficacy and accessibility, encouraging wider consumer adoption. Global beauty giants and indie brands alike are investing heavily in anti-pollution R&D, launching innovative product lines that target specific skin concerns caused by pollutants such as dullness, inflammation, and loss of elasticity. Rising disposable incomes, especially in emerging economies, are enabling consumers to explore premium skincare categories, including pollution-specific treatments. The influence of social media and digital marketing is another strong catalyst, as brands use influencer partnerships, educational content, and interactive tools to raise awareness and demonstrate efficacy. E-commerce and cross-border trade platforms have made it easier than ever for consumers to access niche and global skincare brands, expanding market reach. Additionally, the global emphasis on preventive healthcare and the growing intersection of beauty and wellness are encouraging consumers to invest in skincare as a long-term health measure. Sustainability and “clean beauty” trends are also reinforcing consumer trust in products that offer pollution protection without harmful ingredients. Collectively, these dynamics are positioning anti-pollution skincare as one of the fastest-growing segments in the global beauty and personal care industry.

SCOPE OF STUDY:

The report analyzes the Anti-Pollution Skincare Products market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Anti-Pollution Creams, Anti-Pollution Moisturizers, Anti-Pollution Face Masks, Other Product Types); Distribution Channel (Supermarkets / Hypermarkets, Departmental Stores, Online Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -
  • Amorepacific Corporation
  • Beiersdorf AG
  • Burt`s Bees (Clorox)
  • Clarins Group
  • Coty Inc.
  • Dr. Brandt Skincare
  • Estée Lauder Companies
  • Garnier (L’Oréal)
  • GlaxoSmithKline (GSK)
  • Innisfree (Amorepacific)
  • Johnson & Johnson
  • Kiehl`s (L’Oréal)
  • L`Oréal Group
  • La Roche-Posay (L’Oréal)
  • Neutrogena (Johnson & Johnson)
  • Nivea (Beiersdorf)
  • Olay (Procter & Gamble)
  • Shiseido Company
  • The Body Shop
  • Vichy (L’Oréal)
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Wet AMD, DME, and Cancer Throws the Spotlight on Anti-VEGF Therapies
OEMs Offering Longer-Acting Intravitreal Injections Reduce Treatment Burden in Retinal Disorders
Use in Oncology for Inhibiting Tumor Angiogenesis Expands Indications Beyond Ophthalmology
Growth in Biosimilars and Alternative Delivery Methods Enhances Market Accessibility
OEM Focus on Port Delivery Systems and Implantable Devices Extends Dosing Intervals
Expansion of Personalized Medicine Drives Patient-Specific VEGF Inhibitor Selection
Use in Diabetic Retinopathy and Retinal Vein Occlusion Enhances Clinical Breadth
OEM Development of Topical and Systemic Anti-VEGF Options Drives Pipeline Innovation
Increased Global Screening for Eye Conditions Spurs Early and Sustained Treatment Adoption
Integration With Optical Coherence Tomography (OCT) Enables Precision Dosing Decisions
OEMs Targeting Reduced Inflammation and Immune Activation Improve Tolerability
Growth in Multi-Target Biologics Combining VEGF With Other Pathways Expands Future Potential
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Macular Edema Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Macular Edema Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Macular Edema Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Diabetic Retinopathy Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Diabetic Retinopathy Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Retinal Vein Occlusion Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Retinal Vein Occlusion Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Age-Related Macular Degeneration Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Age-Related Macular Degeneration Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Age-Related Macular Degeneration Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: Canada 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
JAPAN
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: Japan 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: Japan 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
CHINA
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: China 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: China 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
EUROPE
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
FRANCE
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: France 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: France 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
GERMANY
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: Germany 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: Germany 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: Italy 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: Italy 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED KINGDOM
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: UK 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: UK 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: Spain 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Spain 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Russia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Russia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AUSTRALIA
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: Australia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Australia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
INDIA
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: India 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: India 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
LATIN AMERICA
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
MIDDLE EAST
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: Iran 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: Iran 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: Israel 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: Israel 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: UAE 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: UAE 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
AFRICA
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Africa 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by Disease - Percentage Breakdown of Value Sales for Macular Edema Disease, Diabetic Retinopathy Disease, Retinal Vein Occlusion Disease and Age-Related Macular Degeneration Disease for the Years 2014, 2025 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Africa 16-Year Perspective for Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings